p40 (BC28) Mouse Monoclonal Primary Antibody

p40 (BC28) is a ready-to-use IHC antibody that enables you to evaluate the expression of p40 (ΔNp63) protein with clinical confidence using the OptiView DAB IHC Detection Kit

Squamous cell carcinoma stained positive with the p40 (BC28) assay using OptiView DAB IHC detection

Adenocarcinoma stained negative with the p40 (BC28) assay using OptiView DAB IHC detection

Squamous cell carcinoma stained positive with the p63 (4A4) assay using ultraView DAB IHC detection

Adenocarcinoma stained positive with the the p63 (4A4) assay using ultraView DAB IHC detection

p40 (BC28) Antibodyp40 (BC28) is a sensitive and specific antibody for the detection of the p40 (ΔNp63) protein. In a panel with other key markers in our portfolio (TTF-1, CK 5/6, Napsin A), p40 (BC28) can provide an accurate and reliable method for differentiating pulmonary adenocarcinoma from squamous cell carcinoma.1

The p40 (BC28) antibody can provide:

High Sensitivity

p40 has been shown to be as sensitive as, if not more sensitive, than p63.2,4,11

Higher Specificity

Multiple studies indicate that p40 has higher specificity in pulmonary squamous cell carcinomas compared to p63.2-11

Suitable Replacement

p40 may offer a suitable replacement for p63 in various tumor types beyond lung (bladder, prostate, breast and head and neck cancers). 7,12-14

Key Marker p40 (BC28) can serve in a panel of other key markers (TTF-1, Napsin A, CK 5/6) to aid in the accurate distinction between adenocarcinomas and squamous cell carcinomas of the lung.1

Consistent Performance

p40 (BC28) is a pre-diluted, ready-to-use assay optimized for use on the BenchMark IHC/ ISH automated staining platforms which provides a workflow solution that may free up resources, lower labor costs and reduce time to results.

p40 (BC28) is shown to be as sensitive as p63 (4A4) in non-small cell lung cancer but more specific. The use of p40 is recommended as a replacement for p63 when subclassifying non-small cell lung cancer to avoid falsely classifying p63+ adenocarcinoma as squamous cell carcinoma.2

Product name Catalog number Ordering number Tests

p40 (BC28) Mouse Monoclonal Primary Antibody 790-4950 07394420001 50

References

1. Wei Zhao, Hui Wang, Yan Peng, Bo Tian, Lei Peng, Da-Chuan Zhang. ∆Np63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol 2014;7(7):4247-4253

2. Bishop, Justin A, Julie Teruya-Feldstein, William H Westra, Giuseppe Pelosi, William D Travis and Natasha Rekhtman. p40 (∆Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology. 2012.

3. Butnor, Kelly J, James L Burchette. [1876] p40 (ΔNp63) and Keratin 34βE12 Provide Greater Diagnostic Accuracy Than p63 in the Evaluation of Small Cell Lung Carcinoma in Small Biopsy Samples. USCAP Abstract. 2013.

4. Chen, Xiangbai, Yunhau Bao, Rebecca Wong, Katerina Politi, Lizhuo Jiao, Scott Gettinger, Robert Homer, David Chieng, Guoping Cai. [351] The Role of p40 Immunostain in the Cytological Differential Diagnosis of Squamous Cell Carcinoma and Adenocarcinoma of the Lung. USCAP Abstract. 2013.

5. Gailey, MP, AM Bellizzi, CS Jensen. [410] Differentiating Small Cell Carcinoma from Squamous Cell Carcinoma on Fine Needle Aspiration: A Head-To-Head Comparison of p40 and p63 Using Cell Block Immunocytochemistry. USCAP Abstract. 2014.

6. Liao, Zhiming, Qiu Yu, Hui Zhang, Weiwei Cai, Jennifer Alleman-Sposeto and Yifei Zhu. Sensitivity and Specificity of p40, p63 and SOX2 Monoclonal Antibodies in Lung Squamous Cell Carcinoma.Poster. 2013.

7. Tacha, David PhD; Ryan Bremer, PhD; Thomas Haas, DO; Weiman Qi, PhD, MD. An Immunohistochemical Analysis of a Newly Developed, Mouse Monoclonal p40 (BC28) Antibody in Lung, Bladder, Skin, Breast, Prostate and Head and Neck Cancers. Arch Pathol Lab Med—Vol 138, October 2014.

8. Nonaka, Daisuke MD. Study of ΔNp63 Expression in Lung Non-Small Cell Carcinomas. Am J Surg Pathol 2012; 36:895–899.

9. Pelosi et al. Δp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer A Novel Two-Hit, Sparing-Material Approach. Journal of Thoracic Oncology. Volume 7, Number 2. February 2012.

10. Tatsumori et al. p40 is the Best Marker for Diagnosing Pulmonary Squamous Cell Carcinoma: Comparison with p63, Cytokeratin 5/6, Desmocollin-3 and Sox2. Appl Immunohistochem Mol Morphol 2014; 22:377–382.

11. Vogt, Adam P, Cynthia Cohen, Momin T Siddiqui. [436] p40 (ΔNp63): A Highly Sensitive and Specific Immuno-histochemical (IHC) Marker for Diagnosing Pulmonary Squamous Cell Carcinomas (SQCC) in Fine Needle Aspirates. USCAP Abstract. 2013.

12. Sailer et al. Comparison of p40 (DNp63) and p63 expression in prostate tissues – which one is the superior diagnostic marker for basal cells? Histopathology. 2013. 63: 50–56.

13. Bishop, Justin A. MD, Elizabeth A. Montgomery, MD and William H. Westra, MD. Use of p40 and p63 Immuno-histochemistry and Human Papillomavirus Testing as Ancillary Tools for the Recognition of Head and Neck Sarcomatoid Carcinoma and Its Distinction From Benign and Malignant Mesenchymal Processes. Am J Surg Pathol. 2014. 38:257–264.

14. Rooper, Lisa, Rajni Sharma, Justin A. Bishop. Polymorphous Low Grade Adenocarcinoma has a Consistent p63+/p40- Immunophenotype that Helps Distinguish it from Adenoid Cystic Carcinoma and Cellular Pleomorphic Adenoma. Head and Neck Pathol. 2014. DOI 10.1007/s12105-014-0554-4

Ventana Medical Systems, Inc.A Member of the Roche Group1910 Innovation Park Dr.Tucson, AZ 85755USA

www.roche.com www.ventana.com

© 2015 Ventana Medical Systems, Inc.

VENTANA and the VENTANA logo are trademarks of Roche. All other trademarks are the property of their respective owners. 5627A-3 0515